rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies
NCT02710500
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
2
Enrollment
INDUSTRY
Sponsor class
Conditions
Dysferlinopathy
Interventions
DRUG:
rAAVrh74.MHCK7.DYSF.DV
Sponsor
Sarepta Therapeutics, Inc.